Latest Sales Growth News

JB Hi-Fi delivered a solid FY26 with record revenue and profit growth, declaring a 22.5% higher dividend and advancing its net-zero emissions goal.

The GPT Group reported a solid first half in 2026, posting 5% growth in funds from operations and expanding its assets under management to $41.6 billion. Major development projects and capital initiatives underpin its steady momentum.

Baby Bunting Group delivered a 6.5% revenue rise to $556 million in FY26, alongside a 33.9% jump in pro forma net profit after tax, driven by its Store of the Future refurbishments and margin expansion.

Meridian Energy navigated a record July electricity demand with robust renewable generation and high hydro inflows, while retail sales volumes grew and wholesale prices fell sharply.

Rua Bioscience has approved a $600,000 convertible note facility aimed at boosting inventory purchases to accelerate its UK market expansion following a major distribution deal.

Elixinol Wellness (ASX: EXL) has posted a record quarterly revenue of A$4.3 million alongside a 45% gross margin, marking a clear shift from its US CBD origins to a diversified Australian wellness platform. Cost reductions and disciplined cash flow management underpin the company’s readiness to scale.

Metcash Limited posted a steady FY26 performance, with group revenue rising to $19.6 billion and EBITDA up 1.9%, driven by growth in Food and digital channels despite challenges in Hardware.

James Hardie Industries posted a 64% jump in Q1 FY27 net sales to $1.475 billion, powered by the AZEK acquisition and solid organic growth. The company exceeded EBITDA guidance and raised its full-year outlook, targeting robust sales and cash flow growth amid cautious housing market assumptions.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

Endeavour Group posted a 1.3% rise in FY26 sales to $12.2 billion but underlying profit slipped as it flagged $372 million in significant asset write-downs and restructuring costs.

OMG Group smashed its July sales record with net sales soaring to approximately $738,000, a 120% jump on last year, reversing typical seasonal declines and boosted by a refreshed Blue Dinosaur brand.